I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| hepatocyte | 5 studies | 50% ± 21% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| hepatocyte | 5 studies | 50% ± 21% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| liver | 3 studies | 26% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 20419.60 | 226 / 226 | 97% | 914.71 | 393 / 406 |
| heart | 84% | 514.68 | 721 / 861 | 0% | 0 | 0 / 0 |
| lung | 75% | 76.59 | 433 / 578 | 6% | 2.22 | 66 / 1155 |
| prostate | 11% | 5.08 | 26 / 245 | 47% | 10.04 | 237 / 502 |
| adipose | 17% | 13.18 | 204 / 1204 | 0% | 0 | 0 / 0 |
| breast | 5% | 3.19 | 25 / 459 | 7% | 13.12 | 77 / 1118 |
| kidney | 4% | 2.38 | 4 / 89 | 4% | 0.65 | 32 / 901 |
| peripheral blood | 7% | 11.45 | 66 / 929 | 0% | 0 | 0 / 0 |
| pancreas | 0% | 0.11 | 1 / 328 | 6% | 0.97 | 10 / 178 |
| intestine | 1% | 0.56 | 9 / 966 | 4% | 1.37 | 22 / 527 |
| blood vessel | 3% | 3.05 | 40 / 1335 | 0% | 0 | 0 / 0 |
| bladder | 0% | 0 | 0 / 21 | 3% | 0.76 | 14 / 504 |
| stomach | 0% | 0.08 | 1 / 359 | 2% | 0.71 | 7 / 286 |
| esophagus | 1% | 0.32 | 8 / 1445 | 2% | 0.27 | 3 / 183 |
| uterus | 1% | 0.16 | 1 / 170 | 2% | 0.08 | 7 / 459 |
| adrenal gland | 1% | 0.29 | 2 / 258 | 1% | 0.04 | 3 / 230 |
| skin | 1% | 0.62 | 13 / 1809 | 1% | 0.05 | 6 / 472 |
| thymus | 1% | 0.39 | 4 / 653 | 0% | 0.01 | 2 / 605 |
| spleen | 1% | 44.85 | 2 / 241 | 0% | 0 | 0 / 0 |
| brain | 0% | 0.20 | 10 / 2642 | 0% | 0.01 | 2 / 705 |
| muscle | 0% | 0.17 | 4 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ovary | 0% | 0 | 0 / 180 | 0% | 0 | 0 / 430 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0052695 | Biological process | cellular glucuronidation |
| GO_0008210 | Biological process | estrogen metabolic process |
| GO_0005789 | Cellular component | endoplasmic reticulum membrane |
| GO_0015020 | Molecular function | glucuronosyltransferase activity |
| GO_0001972 | Molecular function | retinoic acid binding |
| Gene name | UGT2B4 |
| Protein name | UDP-glucuronosyltransferase 2B4 (UDPGT 2B4) (UGT2B4) (EC 2.4.1.17) (HLUG25) (Hyodeoxycholic acid-specific UDPGT) (UDPGTh-1) UDP glucuronosyltransferase family 2 member B4 |
| Synonyms | UGT2B11 |
| Description | FUNCTION: UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile . Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds . Catalyzes the glucuronidation of the endogenous estrogen hormones such as estradiol and estriol . . |
| Accessions | ENST00000510114.1 ENST00000512583.5 [P06133-3] P06133 ENST00000305107.7 [P06133-1] D6RGY0 |
